Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center (VAFC), University of Kansas, Lawrence, Kansas 66047.
MassBiologics of the University of Massachusetts Medical School, Boston, Massachusetts 02126.
J Pharm Sci. 2020 Jan;109(1):407-421. doi: 10.1016/j.xphs.2019.07.018. Epub 2019 Jul 29.
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal disease among children in developing countries, and there are no licensed vaccines to protect against ETEC. Passive immunization by oral delivery of ETEC-specific secretory IgAs (sIgAs) could potentially provide an alternative approach for protection in targeted populations. In this study, a series of physiochemical techniques and an in vitro gastric digestion model were used to characterize and compare key structural attributes and stability profiles of 3 anti-heat-labile enterotoxin mAbs (sIgA1, sIgA2, and IgG1 produced in CHO cells). The mAbs were evaluated in terms of primary structure, N-linked glycan profiles, size and aggregate content, relative apparent solubility, conformational stability, and in vitro antigen binding. Compared to IgG1 mAb, sIgA1 and sIgA2 mAbs showed increased sample heterogeneity, especially in terms of N-glycan composition and the presence of higher molecular weight species. The sIgA mAbs showed overall better physical stability and were more resistant to loss of antigen binding activity during incubation at low pH, 37°C with pepsin. These results are discussed in terms of future challenges to design stable, low-cost formulations of sIgA mAbs as an oral supplement for passive immunization to protect against enteric diseases in the developing world.
肠产毒性大肠杆菌(ETEC)是发展中国家儿童腹泻病的主要病因,目前尚无针对 ETEC 的许可疫苗。通过口服递送 ETEC 特异性分泌型 IgA(sIgA)进行被动免疫可能为目标人群的保护提供一种替代方法。在这项研究中,使用一系列物理化学技术和体外胃消化模型来表征和比较 3 种抗不耐热肠毒素 mAb(在 CHO 细胞中产生的 sIgA1、sIgA2 和 IgG1)的关键结构属性和稳定性特征。根据一级结构、N-连接聚糖谱、大小和聚集体含量、相对表观溶解度、构象稳定性和体外抗原结合对 mAb 进行了评估。与 IgG1 mAb 相比,sIgA1 和 sIgA2 mAb 显示出更高的样品异质性,尤其是在 N-聚糖组成和存在高分子量物种方面。sIgA mAb 总体表现出更好的物理稳定性,并且在低 pH 值、37°C 下与胃蛋白酶孵育时,抗原结合活性的丧失更具抗性。根据未来设计稳定、低成本的 sIgA mAb 制剂的挑战,这些结果在为发展中国家的肠道疾病提供被动免疫口服补充方面进行了讨论。